BOARD OF DIRECTORS

Bret Christensen is a seasoned leader recognized for his exceptional ability to launch innovative solutions, penetrate markets and effectively scale businesses. With over two decades of experience in the healthcare sector, a specialized focus on women’s health and a comprehensive understanding of the broader healthcare landscape, Bret has consistently proven his ability to elevate emerging solutions into market share leaders, solidifying his reputation as a catalyst for growth and success.

Over the course of his distinguished career, Bret has held strategic commercial and general management leadership roles at Hologic (NASDAQ: HOLX), Myriad Genetics (NASDAQ: MYGN) and Insulet (NASDAQ: PODD), where he played a central role in revolutionizing treatments in women’s health care, oncology and diabetes, respectively. His strategic leadership drove significant revenue growth, achieved product commercialization success and advanced groundbreaking therapies that have redefined standards of care.

Bret’s expertise spans diagnostics, therapeutics and medical devices, positioning him as the ideal leader to accelerate Biote to its next level of growth. With a rare blend of business acumen and deep industry insight, he is uniquely equipped to drive Biote’s continued success as a leading educator in hormone optimization and therapeutic wellness while expanding its market presence and reach.

Bret holds a Bachelor of Science from Utah Valley University, a Masters of Business Administration from the University of Utah, David Eccles School of Business and several executive certifications from the University of Chicago Booth School of Business.

Marc Beer brings more than 25 years of development and commercialization experience in biotechnology, pharmaceutical, device, and diagnostics and has served as CEO of Aegerion Pharmaceuticals, Inc. and ViaCell and as a member of the Erytech Pharma Board of Directors.

A member of the Miami University Business Advisory Council, Mark previously served as a member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council.

Marc has led several companies through significant capital raises and public offerings, including Renovia, LumeNXT Inc., Origami Surgical, Liftique, and Minerva Neurosciences Inc. His extensive experience as a Founder, CEO, and Chairman in numerous health-related companies makes him an ideal contributor to support Biote’s growth initiatives.

Andrew R. Heyer is a finance professional with over 40 years of experience investing in the consumer and consumer-related products and services industries, as well as a senior banker in leveraged finance during which time his clients included many large private equity firms. Andrew served as the President and a director of Haymaker III until it completed its business combination with Biote in May 2022.

Currently, Andrew serves as the Chief Executive Officer and Founder of Mistral, a private equity fund manager founded in 2007 that invests in the consumer industry. He has extensive leadership experience, including Trimaran Capital Partners, CIBC World Markets Corp., CIBC Argosy Merchant Banking Funds, Drexel Burnham Lambert Incorporated, and Shearson/American Express.

Andrew currently serves on the boards of Tastemaker Acquisition Corp. and AF Acquisition Corp., and has had previous board experience at The Hain Celestial Group, Inc., Worldwise, Inc., The Lovesac Company, Inc., and Insomnia Cookies.

He received his B.Sc. and M.B.A. from the Wharton School of the University of Pennsylvania, graduating magna cum laude.

Rich Barrera is the Founder, CEO, and Portfolio Manager of Roystone Capital Management and Co-Founder and Partner of Brighton Health Partners, both New York-based investment firms. Roystone, founded in 2013, invested in growth, corporate event, and value-oriented situations across the capital structure, managing over $3.0 billion at its peak. In 2019, Roystone returned third-party capital to focus on more concentrated, long-term investments. Brighton Health Partners, founded in 2021, focuses on healthcare services businesses through a hands-on “Partner Equity” approach with mission-driven entrepreneurs.

Rich has extensive experience negotiating complex transactions, public markets investing, and capital markets execution, along with significant board and governance experience. From 2019 to 2020, he served on the board of PG&E, chairing the Finance Committee during its $25 billion wildfire liability settlement and $20+ billion capital raise to exit bankruptcy.

He previously held senior investment roles at Redwood Capital, Glenview Capital, and JP Morgan. Mr. Barrera earned a BSE from the Wharton School and an MBA from Harvard Business School, and serves on the boards of several private companies and Success Academies, New York City’s largest charter school network.

At Vector Medical Group, Dana Jacoby leads a team of expert consultants. Her expertise spans numerous medical specialties including gastroenterology, dermatology, orthopedics, oncology, dermatology, and retina. Her consulting work is informed by market data, measurement and analytics, strategy design, implementation, and technology innovation. She has personally consulted with over 75% of all urology practices in the US.

As owner of several companies, Dana has overseen multiple mergers and private equity transactions. Additionally, she’s consulted for up to $1 billion in mergers and acquisitions, making her one of the most sought-after healthcare specialists in the U.S.

Dana has worked for individual providers as well as large corporate healthcare companies including General Electric Healthcare and Johnson & Johnson. At Allergen, a global Pharmaceutical Company, she helped launch Botox in Asia.

In her spare time, Dana is an avid runner and Boston Marathon qualifier and has run 68 marathons, including one in every US state and on every continent except Antarctica.

Dr. Cone is a seasoned physician executive with leadership experience in multiple healthcare organizations. He is currently the President of Privia Medical Group Gulf Coast, a 350 provider multi-specialty group serving the Gulf Coast market of Texas, with offices in Houston, Austin and San Antonio. He has been a private practice OB-Gyn for 31 years and delivered over 10,000 babies during his career. He is the Market President for Privia Health, a national physician enablement company, facilitating physicians making the transition from fee for service reimbursement models to value based care and risk bearing products.  He is the Vice President of US Women’s Health Alliance, a national organization representing over 5,000 OB-Gyn providers, promoting women’s health and supporting independent OB-Gyn practices. He is Chairman of the Board for Global Women’s Health Providers, a Cedar Gate company focused on OB Bundled Payment programs. He serves on the Board of Directors of BioTe Medical, a Nasdaq company and Chairs the Advisory Board for Fannin Surgicare, an ambulatory Surgery Center. In addition to his passion for patient care and making doctor’s lives better, he enjoys hunting, fishing and college sports. He is a graduate of Texas A&M University and Baylor College of Medicine, where he also did his residency. He is married with three children.

Debby Morris brings over 40 years’ experience in executive leadership in healthcare services as well as other service industries. She currently serves as President of AccessHope. Prior to that, she served as the Executive Vice President, Chief Financial Officer of Apria Healthcare (Nasdaq:APR), a leading provider of home healthcare equipment and related services in the United States where she led both financial and operational aspects of the business.

Debby brings a breadth of operational and financial experience in both private and public, national, and multi-national companies, including supply chain, data analytics, SEC Reporting, BOD governance, Investor Relations, M&A, business transformation, and leading large corporate transactions including taking Apria public in 2021 and completing the sale of Apria in 2022.

She currently serves as a director for Rexford Industrial (NYSE: REXR) and serves on the compensation and nomination and governance committees and also serves as a director for Progyny, Inc. (Nasdaq: PGNY) and serves on the audit committee.